Clinical Significance and Different Expression of Dipeptidyl Peptidase Iv and Procalcitonin in Mild and Severe Covid-19 Publisher



Jamaati H¹ ; Tabarsi P² ; Bahrami N^{3, 4} ; Yasari F¹ ; Varahram M⁵ ; Dizaji MK⁶ ; Hashemian SMR¹ ; Daustani M⁷ ; Emami M¹ ; Shirian S^{8, 9, 10} ; Masumi L¹¹ ; Rasouli A¹² ; Narimani A¹³ ; Ahmadian N¹⁴ Show All Authors Show Affiliations
Source: Journal of Cellular and Molecular Anesthesia Published:2021

Abstract

Background: Coronavirus has become a global concern in 2019-20. The virus belongs to the coronavirus family, which has been able to infect many patients and victims around the world. The virus originated in the Chinese city of Wuhan, which eventually spread around the world and became a pandemic. Materials and Methods: A total of 60 Patients with severe (n=30) and mild (n=30) symptoms of COIVD-19 were included in this study. Peripheral blood samples were collected from the patients. Real-time PCR was used to compare the relative expression levels of Procalcitonin and dipeptidyl peptidase IV (DPPIV) in a patient with severe and mild Covid-19 infection. Results: Procalcitonin and dipeptidyl peptidase IV markers in the peripheral blood of patients with severe symptoms, were positive in 29 (96.60%) and 26 (86.60%), respectively (n=30); however, positive rates in the mild symptoms patients group were 27 (90%) and 25 (83.30%), respectively. There was a statistically significant difference between these two groups in terms of DDPIV and Procalcitonin (p<0.001). Conclusion: Procalcitonin and DPPIV increase in patients with COVID-19 infection, significantly higher in the patients with more severe clinical symptoms than those with milder ones. More studies will be needed to verify the reliability of the current findings. © 2021 Vaclav Skala Union Agency. All right reserved.